NICE rejects Gilead CAR-T cancer cell therapy

The company ' s CAR-T drug Yescarta, which had just received approval from the European Commission for two aggressive forms of non-Hodgkin lymphoma, was found to be too expensive according to Britain ’s state-funded health service.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news